Adverse Pregnancy Outcomes Partly Mediate Association Between Prepregnancy Obesity, CVD Risk
By Elana Gotkine HealthDay Reporter
MONDAY, April 21, 2025 -- Adverse pregnancy outcomes (APOs) mediate a small proportion of the association between prepregnancy obesity and cardiovascular disease (CVD) risk in midlife, according to a study published in the April 22 issue of the Journal of the American College of Cardiology.
Jaclyn D. Borrowman, Ph.D., from Northwestern University in Chicago, and colleagues examined the extent to which prepregnancy body mass index (BMI) and CVD risk factors in midlife are mediated by APOs in a study involving 4,269 pregnant participants, aged 18 years or older, enrolled at 28 weeks of gestation without prepregnancy hypertension or diabetes. At 11.6 ± 1.3 years after delivery, participants had a follow-up visit.
Overall, gestational diabetes mellitus (GDM) and new-onset hypertensive disorders of pregnancy (HDP) occurred in 13.8 and 10.7 percent of participants, respectively. The researchers found that those with prepregnancy obesity had higher mean arterial pressure (7.0 mm Hg), triglycerides (28.5 mg/dL), and hemoglobin A1c (0.3 percent) at follow-up compared with those with a normal prepregnancy BMI. The association between obesity and hemoglobin A1c was partially mediated by GDM (24.6 percent), while the association between obesity and mean arterial pressure was partially mediated by new-onset HDP (12.4 percent).
"These data suggest that APOs represent a clinically significant marker of future CVD risk that is unmasked during the stress of pregnancy and highlights key vascular and metabolic pathways, which has important implications in designing preventive strategies," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Tirzepatide Dispensations Increased Rapidly After Approval
TUESDAY, April 15, 2025 -- After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among...
Adverse Events From Semaglutide Seen in the ED Usually GI-Related
TUESDAY, April 15, 2025 -- The rate of emergency department visits for adverse events among patients dispensed semaglutide is low, with most visits involving gastrointestinal...
Roux-en-Y Gastric Bypass, Sleeve Gastrectomy Beat Adjustable Gastric Banding for Severe Obesity
THURSDAY, April 10, 2025 -- For adults with severe obesity, Roux-en-Y gastric bypass and sleeve gastrectomy are more effective than adjustable gastric banding, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.